Using a genetically engineered mouse melanoma model we demonstrate that targeted activation of the type I IFN system with immunostimulatory RNA in combination with blockade of immune inhibitory receptors is a rational strategy to expose immune cell-poor tumors to cellular immune surveillance.
Introduction
Primary and metastatic human melanomas show considerable variability in the composition, density and distribution of tumor-infiltrating immune cells in different patients. In agreement with the tumor immune surveillance theory, several studies found a correlation between the presence of T cells in primary melanomas, the expression of MHC class I molecules on tumor cells and a favorable prognosis (1, 2) . Conversely, the absence of tumor-infiltrating T cells in primary melanomas was associated with an increased risk for metastatic spread into the sentinel lymph nodes and decreased survival (3, 4) . The underlying mechanisms that recruit immune cells and regulate their function in the tumor microenvironment are poorly understood. Previously, we described an association between the presence of granzyme B expressing T lymphocytes and a locally activated type I IFN system, indicated by expression of the antiviral protein MxA, in primary melanomas of patients showing signs of spontaneous regression (5) . The rationale for our analyses was derived from our observations in experimental mouse models with transplantable tumors, including the B16 melanoma, where local transgenic expression of IFN-alpha could augment CTL responses in the tumor microenvironment (6) (7) (8) . More recently it was shown that activation of the host type I IFN system is indeed a critical requirement for innate immune recognition of transplanted B16 melanomas through signaling on CD8Į+ DCs which then initiate adaptive cellular immunity (9, 10) .
However, melanomas also frequently progress despite T cell infiltration. This was originally thought to be due to the Darwinian selection of tumor cell variants that escape immune destruction (11) . As an alternative explanation it was found that T cells loose their effector functions in the immunosuppressive microenvironment of tumors where regulatory immune cell subpopulations accumulate (12) . More recently, dynamic adaptive changes of both tumor and immune cells caused by inflammatory cytokines have been described that contribute to the immune escape of melanoma (13- Given the success of new immunotherapies that abrogate the immune-inhibitory PD-L1/PD-1 interactions in melanoma patients with pre-existing anti-tumor immunity (16, 20) , the treatment of patients with melanomas lacking T cell infiltrates ("immune cell poor melanomas") has emerged as a major clinical challenge. We experimentally addressed this issue in the genetically engineered Hgf-
Cdk4
R24C mouse model where primary melanomas histomorphologically imitate human pigmented melanomas with little immune cell infiltration and metastasize early in lymph nodes and lungs (22). In our work we investigated three principle hypotheses: 1) immune cell-poor primary melanomas evade innate type I IFN-dependent immune surveillance and thereby avoid the induction of anti-tumoral cytotoxic T cell immunity; 2) targeted activation of type I IFNs can establish cellular immune surveillance; 3) type I IFNs simultaneously activate immune-inhibitory PD-L1/PD-1 receptor interactions and therapeutic blockade of this pathway further augments tumor immune surveillance.
Results

Immune cell poor melanomas evade type I IFN-dependent immune surveillance and editing
Based on our immunohistochemical observation that regressive primary melanomas with extensive T cell infiltration stain positive for markers of an activated type I IFN system (5), we expected that immune cell poor melanomas lacking T cells would show only low expression levels of type I IFN regulated genes. A bioinformatic analysis of genome-wide transcriptomic data for 223 primary melanomas (23) indeed showed that the expression of CD3D and other T cell transcripts directly correlated with the expression of a set of genes that are regulated by type I IFNs (Pearson correlation coefficient 0,6) in melanoma cells (Fig. 1A ,B and Suppl. Table S1 ). The type I IFN response signature was generated from a publicly available data set of IFN alpha treated human melanoma cells (24) .
Furthermore, high expression of type I IFN responsive genes or CD3D was associated with an increased relapse-free survival, consistent with the idea that preexisting antitumoral immune responses determine a favorable prognosis of melanoma patients (Fig. 1C ).
In turn, the absence of IFN-regulated genes in immune cell poor melanomas suggested that these We therefore crossed Hgf-Cdk4 R24C into the Ifnar1 -/-background to obtain melanoma-prone mice that lack a functional type I IFN system. Cohorts of 8 week old Ifnar1-competent and Ifnar1-deficient HgfCdk4 R24C mice then received a single epicutaneous application of the carcinogen 7,12-dimethylbenz(a)anthracene (DMBA) on the back skin ( Fig. 2A ) to accelerate and synchronize the development of primary melanomas (13) . We found that DMBA-initiated primary melanomas appeared with the same growth kinetics and multiplicity in the skin of Ifnar1-deficient and Ifnar1-competent HgfCdk4 R24C mice (Fig. 2B) . Accordingly, DMBA-exposed Ifnar1-deficient and Ifnar1-competent HgfCdk4 R24C mice showed largely identical survival curves (Fig. 2C ). These results indicated that the development of primary melanomas in this experimental system was not affected by type I IFNdependent immune surveillance.
In subsequent experiments we injected cohorts of Ifnar1-competent and Ifnar1-deficient Hgf-Cdk4 R24C mice subcutaneously with the carcinogen methylcholanthrene (MCA) to induce primary fibrosarcomas (Fig. 2D ). In line with previously reported experimental work in this well-established model for IFNdependent cancer immune surveillance (25), we found that fibrosarcomas developed with decreased latency and increased penetrance in Ifnar1-deficient compared to Ifnar1-competent Hgf-Cdk4 R24C mice (Fig. 2E ) resulting in shorter survival (Fig. 2F ). This ruled out the possibility that the anti-inflammatory properties of HGF, which can promote a tolerogenic dendritic cell phenotype and the expansion of regulatory T cells (26, 27) , precluded immune surveillance by the type I IFN system in Hgf-Cdk4 R24C mice.
To understand the divergent role of the type I IFN system in the pathogenesis of primary melanomas and fibrosarcomas we performed further morphological, cellular and molecular investigations.
Immunohistopathological analyses revealed increased numbers of tumor-infiltrating CD45 + immune cells in primary MCA-induced fibrosarcomas when compared to primary DMBA-induced melanomas in
Hgf-Cdk4 R24C mice (Fig. 2G) . This difference was further quantified and confirmed to be significant by flow cytometric analyses of tumor cell suspensions (Fig. 2H, left) . Fibrosarcomas showed increased
Research. Ifnar1-deficient and Rag2-deficient syngeneic C57BL/6 mice ( Fig. 3A) . Each transplanted melanoma grew progressively in all three strains of mice (Fig. 3B, C) , indicating the poor immunogenicity of both Ifnar1-competent and Ifnar1-deficient melanomas. Interestingly, a subset of Ifnar1-competent anddeficient melanoma cells grew more rapidly in Ifnar1-deficient mice when compared to Ifnar1-competent or Rag2-deficient mice, pointing towards the previously described role for the host type I IFN system in transplanted melanoma (9) .
Targeted type I IFN activation establishes immune surveillance and impairs melanoma growth
We hypothesized that therapeutic activation of type I IFNs in the microenvironment of primary HgfCdk4 R24C melanomas could alert innate immune surveillance and thereby delay tumor growth. As an experimental strategy we used the prototypic immunostimulatory RNA polyinosinic:polycytidylic acid (poly(I:C)) which triggers the innate viral recognition receptors TLR3 and MDA5 and efficiently stimulates the type I IFN system (28, 29) . Peritumoral injections of established DMBA-induced primary Hgf-Cdk4 R24C melanomas with poly(I:C) for two weeks strongly induced the expression of type I IFNregulated genes and promoted the recruitment of immune cells into the tumor microenvironment ( Fig.   4A , B). Prolonged treatment with poly(I:C) considerably delayed the growth of primary melanomas and increased survival (Fig. 4C, D) . This effect was completely abrogated in Ifnar1-deficient Hgf-Cdk4 R24C mice (Fig. 4E) . Thus, targeted type I IFN activation with poly(I:C) exposed immune cell-poor HgfCdk4 R24C melanomas to the surveillance functions of cellular immunity.
Research. Short term treatment of established HCmel3 melanomas with poly(I:C) for two weeks (Fig. 4F ) also stimulated type I IFN-regulated genes and increased the number of immune cells in the tumor microenvironment to a similar extent when compared with primary melanomas (Fig. 4B, G) . Prolonged poly(I:C) treatment delayed the growth of transplanted HCmel3 melanomas and significantly increased survival (Fig. 4H, I ). Transplanted HCmel3 cells grow with similar kinetics in Ifnar1-competent and Ifnar1-deficient mice (Fig 4I, J , left panel), demonstrating that this melanoma cell line does not spontaneously engage the host type I IFN system in the transplantation setting. Importantly, the therapeutic efficacy of poly(I:C) was completely abrogated in Ifnar1-deficient C57BL/6 mice ( (Fig. 4D, I ). Both type I and type II IFNs up-regulated the expression of PD-L1 on the Hgf-Cdk4 R24C melanoma cell line HCmel3 in vitro (Fig. 6A) . We also observed a significant up-regulation of PD-L1 mRNA expression levels in poly(I:C) treated compared to untreated
Hgf-Cdk4 R24C mouse melanomas that correlated with the upregulation of type I IFN-regulated genes such as IRF7 (Fig. 6B ). Melanoma-bearing mice treated with poly(I:C) also showed increased numbers of PD-1 expressing CD8+ T cells in the peripheral blood ( analysis of PD-L1 expression in the primary melanoma dataset shown in Figure 1B . Therefore we interrogated two additional publicly available datasets of either primary melanomas (GSE15605) or melanoma metastasis (TCGA skin cutaneous melanoma) that were generated using a different microarray platform (37) or RNA seq, respectively. Indeed, this analysis confirmed our hypothesis, as we found a strong correlation between CD3D, IFN-responsive genes and PD-L1 expression in both datasets irrespectively of the genomics platform (Fig. 7A, B) . Clinical follow-up data was available for the TCGA melanoma metastasis cohort and we classified samples by unbiased median expression value cutoffs as described for the primary melanoma cohort shown in Figure 1B . Consistently, high expression levels of CD3D, IFN-responsive gene and importantly also PD-L1 were associated with a favorable disease course (Fig. 7C) .
Discussion
In our work we experimentally investigated the role of type I IFN-dependent tumor immune surveillance in a genetically engineered mouse model of melanoma. By crossing the Hgf-Cdk4 In contrast to DMBA-induced melanomas, we found that primary MCA-induced sarcomas spontaneously activated the host type I IFN system in Hgf-Cdk4 R24C mice, confirming a previously published report (25) . Since both tumor types were induced by chemically related and highly potent carcinogens, one would expect a similar spectrum of tumor antigens due to genetic mutations. The divergent interaction of primary melanomas and sarcomas with the innate immune system might therefore reflect the different immunological properties of the cells of origin, e.g. melanocytes vs.
fibroblasts. It is tempting to speculate that malignant fibrosarcoma cells dictate an immunologically much more active microenvironment as they express higher levels of MHC class I molecules and secrete increased amounts of proinflammatory chemokines and cytokines when compared to malignant melanoma cells. Our observations are in line with recent reports in genetically engineered mouse models where malignant transformation in lung epithelial cells (38) or muscle cells (39) 
cell poor melanoma not only highlights the critical importance of immune-inhibitory PD-L1/PD-1 interactions in vivo but also provides a pre-clinical proof of concept that targeted type I IFN activation is a rational strategy to increase the therapeutic benefit of PD-1/PD-L1 blockade also for patients with immune cell-poor melanomas. These insights underscore the clinical relevance of our work and provide a rationale for further experimental investigations to develop similar combination treatment protocols. These may further augment cytotoxic immunity by additionally targeting other IFN-driven counter-regulatory mechanisms which attenuate NK and T cell effector functions in the tumor microenvironment (49).
Methods
Mice.
Wild-type, Ifnar1
-/-and Rag2 -/-C57BL/6 mice were purchased from the Jackson Laboratory. Ifnar1 
Induction and analysis of primary melanomas and primary sarcomas.
The development of primary melanomas on the shaved back skins of 8 week old Ifnar1-competent and Ifnar1-deficient Hgf-Cdk4 R24C mice was accelerated and synchronized by a single epicutaneous application of 100 nmol 7,12-dimethylbenz(a)anthracene (DMBA) as described previously (13) .
Alternatively, mice received a single subcutaneous injection of 100 μg 3-methylcholanthrene (MCA)
into the flank to induce fibrosarcomas. Tumor development was monitored by inspection, palpation and digital photography. Tumor sizes were measured weekly using a vernier calliper and recorded as mean diameter. Mice were sacrificed when progressively growing melanomas or sarcomas exceeded 10 mm or when signs of illness were observed.
Serial tumor transplantation.
Research. 
HCmel3 tumor transplantation.
The HCmel3 melanoma cell line was generated from a primary Hgf-Cdk4 R24C melanoma as described previously (13) . Groups of syngeneic C57BL/6 mice were injected intracutaneously with 4x10 Repeated-dose acute toxicity study.
To evaluate the potential toxicity of the combination treatment with 50 μg poly(I:C) intracutaneously and 250 μg anti-PD1 antibodies intraperitoneally groups of C57BL/6 mice were treated twice weekly for four weeks. A control group of mice was injected with identical volumes of PBS intracutaneously and intraperitoneally. The body weight and general health was observed and documented for 28 days.
At necropsy 4 days after the last therapeutic dose blood was collected for clinical chemistry and 
Histology and immunohistology.
Mouse tumors were immersed in a zinc-based fixative (BD Pharmingen) and human melanoma samples in buffered paraformaldehyde (DAKO). Informed consent to use melanoma biopsy material for scientific purposes was obtained from all patients. Tissues were embedded in paraffin and sections stained with H&E according to standard protocols. Immunohistochemistry was performed with rat antimouse CD45 mAb (BD Biosciences) followed by enzyme-conjugated secondary antibodies and the LSAB-2 color development system (DAKO). Heavily pigmented mouse melanomas were bleached before staining (20 min at 37°C in 30% H 2 O 2 and 0.5% KOH, 20 sec in 1% acetic acid and 5 min in TRIS buffer). Stained sections were examined with a Leica DMLB microscope. Images were acquired with a JVC digital camera KY-75FU and processed with Adobe Photoshop.
Flow cytometry.
Melanoma-infiltrating immune cells were isolated and stained with fluorochrome-conjugated mAbs specific for mouse CD45, CD11b, CD8, Nk1. 
Real-time RT-PCR.
Tumor samples were harvested and immediately snap frozen in liquid nitrogen. Total RNA was isolated using TRI Reagent (Sigma-Aldrich) and purified using RNeasy columns (Qiagen). Reverse 
Cell culture and treatment of HCmel3 melanoma cells.
HCmel3 melanoma cells were generated from primary Hgf-Cdk4 R24C mouse melanomas in our laboratory and cultured in complete RPMI 1640 medium containing 10% FCS (Biochrome), 2 mM Lglutamine (Gibco), 10 mM non-essential amino acids (Gibco), 1 mM HEPES (Gibco), 20 μM 2-mercaptoethanol, 100 IU/ml penicillin and 100 mg/ml streptomycin (Invitrogen). HCmel3 cells were authenticated by genomic PCR for the Hgf transgene and the Cdk4 R24C knockin alleles. Melanoma cells were seeded in 6-well plates and treated with 1,000 U/ml recombinant mouse IFN-Į (PBL) or
IFN-Ȗ (Peprotech). After 24 h of stimulation surface expression of MHC I and PD-L1 was analyzed.
Statistical analyses.
Statistical analyses of experimental results were evaluated with the GraphPad Prism 4 software. Twotailed Student's t-test analyses were preformed as indicated. Results were considered statistically significant when p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***).
Bioinformatic analyses of gene expression array data for human melanomas.
Research. We used the R programming environment and the Bioconductor platform for our bioinformatic analysis. The GSE19428 dataset was used to identify a core signature of type I interferon (Interferon alpha) induced genes across five human melanoma cell lines (Referred as type I interferon response signature). The gene expression data (GSE19428_series_matrix.txt) was downloaded as normalized data using global scaling with a trimmed mean target intensity of each array set to 100 (24) . data.nci.nih.gov/tcga/) using the Data Matrix download option. We used the data columns "vital status", "days to death", "days to last follow-up" and "tumor tissue site" to select samples from melanoma metastasis and to analyze survival in cohorts stratified by median gene expression level cutoffs. Primary melanomas were excluded due to low case numbers and short prospective clinical follow-up. We included only samples from regional lymph node metastasis, regional cutaneous or subcutaneous metastasis (including satellite and in-transit metastasis) and distant metastasis at various anatomic sites such as trunk, extremities and head/neck region. We obtained a total of 248 samples with clinical annotation and RNA seq gene expression data. For convenience the survival data provided as "days to death" and "days to last follow-up" was transformed to "years to death" and "years to last follow-up". Within this selected TGCA metastasis cohort, the clinical follow-up of many cases started far before the sample collection and molecular characterization of the respective metastatic lesion that occurred later in the course of the disease. As exemplification, the cohort contains many samples from metastatic lesions of patients that were initially diagnosed with a nonmetastatic e.g. stage I or stage II melanoma several years ago, but have developed a melanoma metastasis later in the course of their disease. Hence, survival ("days to death or last follow-up") reflects a combination of retrospective and prospective survival data since initiation of the clinical follow-up and serves as an assessment of the overall disease course.
RNA seq read counts were log2 normalized and unbiased median gene expression value cutoffs were applied for the analysis of high/low gene expression subgroups and their potential associations with overall disease outcome ("days to death or last follow-up"). Expression values of the type I interferon response signature genes were averaged (mean) prior to calculation of the median expression cutoff value. Overall survival was calculated by the Kaplan-Meier method and significance was determined by the log-rank test.
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